AAVV: "Coping with ch14.18", Children's Neuroblastoma Cancer Foundation , 31 July 2012 (2012-07-31), Retrieved from the Internet: URL:http://www.cncfhope.org/cms_images/fil e_466.pdf [retrieved on 2017-12-18] (B1)

ALICE L. YU ET AL: "Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma", NEW ENGLAND JOURNAL OF MEDICINE, vol. 363, no. 14, 30 September 2010 (2010-09-30), pages 1324-1334, XP055045834, ISSN: 0028-4793, DOI: 10.1056/NEJMoa0911123 cited in the application (B1)

Anonymous: "HiGH RISK NEUROBLASTOMA STUDY 1 OF SIOP-EUROPE (SIOPEN)", SIOP , 1 July 2009 (2009-07-01), pages 1-303, XP002722380, Retrieved from the Internet: URL:http://www.oncauvergne.fr/index.php?op tion=com_docman&task=doc_download&gid=928& Itemid= [retrieved on 2014-03-27] (B1)

Anonymous: "Press Release: Oncology Alliance. Apeiron, CCRI and SIOPEN Join Forces against Neuroblastoma.", Apeiron Biologics AG. , 22 June 2011 (2011-06-22), page 8PP, XP002722247, Vienna Retrieved from the Internet: URL:http://www.life-sciences-germany.com/n ews/apeiron-ccri-siopen-neuroblastoma-biol ogics-group-forschungs-und-2001-97329.html [retrieved on 2014-03-20] (B1)

GAINS JENNIFER ET AL: "Ten challenges in the management of neuroblastoma.", FUTURE ONCOLOGY, vol. 8, no. 7, July 2012 (2012-07), pages 839-858, XP002722246, (LONDON, ENGLAND) ISSN: 1744-8301 (B1)

HOLGER LODE ET AL: "Long-term continuous infusion of anti-GD2 antibody CH14.18/CHO in relapsed/refractory neuroblastoma patients", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 1, no. Suppl 1, P244, 7 November 2013 (2013-11-07), XP021167203, BIOMED CENTRAL LTD, LONDON, UK ISSN: 2051-1426, DOI: 10.1186/2051-1426-1-S1-P244 (B1)

VICTORIA CASTEL ET AL: "Treatment of high-risk neuroblastoma with anti-GD2 antibodies", CLINICAL AND TRANSLATIONAL ONCOLOGY, vol. 12, no. 12, 1 December 2010 (2010-12-01), pages 788-793, XP055109508, ISSN: 1699-048X, DOI: 10.1007/s12094-010-0600-y (B1)

LADENSTEIN R ET AL.: "Ch14.18 antibody produced in CHO cells in relapsed or refractory stage 4 neuroblastoma patient.", MABS, vol. 5, no. 5, 31 May 2013 (2013-05-31), pages 801-809, (B1)

LODE H AND DOBKE J: "A Phase I/II Dose Schedule Finding Study of ch14.18/CHO Continuous Infusion Combined with Subcutaneous Aldesleukin (=Proleukin) (IL-2) in Patients with Primary Refractory or Relapsed Neuroblastoma. A SIOPEN Study", INTERNET CITATION, 11 April 2012 (2012-04-11), pages 1-3, XP002688973, Retrieved from the Internet: URL:http://www.kinderkrebsinfo.de/health_p rofessionals/clinical_trials/phase_i___ii_ trials_in_the_gpoh/longterminfusion_study_ lti_ch1418/index_eng.html [retrieved on 2012-12-10] (B1)

MURRAY J L ET AL: "Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors", JOURNAL OF CLINICAL ONCOLOGY, vol. 12, no. 1, 1 January 1994 (1994-01-01), pages 184-193, XP009165391, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US ISSN: 0732-183X (B1)

R. HANDGRETINGER ET AL: "A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma", EUROPEAN JOURNAL OF CANCER, vol. 31, no. 2, 1 January 1995 (1995-01-01), pages 261-267, XP055045925, ISSN: 0959-8049, DOI: 10.1016/0959-8049(94)00413-Y (B1)

T. SIMON: "Consolidation Treatment With Chimeric Anti-GD2-Antibody ch14.18 in Children Older Than 1 Year With Metastatic Neuroblastoma", JOURNAL OF CLINICAL ONCOLOGY, vol. 22, no. 17, 26 July 2004 (2004-07-26) , pages 3549-3557, XP055109509, ISSN: 0732-183X, DOI: 10.1200/JCO.2004.08.143 (B1)

KUSHNER B H ET AL: "Phase II trial of the anti-GD2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma", JOURNAL OF CLINICAL ONCOLOGY, vol. 19, no. 22, 15 November 2001 (2001-11-15), pages 4189-4194, XP002714904, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US ISSN: 0732-183X (B1)